Quoin Pharmaceuticals Ltd - רווח נקי למניה בארבעת הרבעונים האחרונים QNRX

How stable is the operational environment for Quoin Pharmaceuticals (QNRX)? Despite a neutral environment, Quoin Pharmaceuticals (QNRX) remains vulnerable to raw material supply disruptions and regulatory barriers. However, orphan drug status and successes in treating Netherton syndrome are driving growth. The annual EPS growth rate over the last 12 months confirms these trends, with the metric currently standing at 98.70.
QNRX (Quoin Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To build a high-quality portfolio, I analyze earnings stability through EPS dynamics. This indicator measures the percentage change in net income per share over a rolling twelve-month period. For Quoin Pharmaceuticals (QNRX), such a metric reflects the efficiency of capitalizing developments in Netherton syndrome therapy. Growth in this figure confirms the biotech business's ability to monetize innovations. By analyzing historical year-over-year EPS growth (TTM), an investor determines the actual stage of drug commercialization.